PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
2534417-0	1989	Effect of a new angiotensin converting enzyme inhibitor, cilazapril, on circulating atrial natriuretic factor during exercise in patients with essential hypertension.	Cilazapril	57-67	natriuretic peptide A	Homo sapiens	84-109	
2534417-1	1989	In seven patients with mild to moderate essential hypertension, the effect of a new angiotensin converting enzyme (ACE) inhibitor, cilazapril, on atrial natriuretic factor (ANF) was examined at rest and during exercise.	Cilazapril	131-141	natriuretic peptide A	Homo sapiens	146-171	
2534417-1	1989	In seven patients with mild to moderate essential hypertension, the effect of a new angiotensin converting enzyme (ACE) inhibitor, cilazapril, on atrial natriuretic factor (ANF) was examined at rest and during exercise.	Cilazapril	131-141	natriuretic peptide A	Homo sapiens	173-176	
2534417-5	1989	The plasma ANF level was increased by exercise, but at the 75-W workload it was decreased by cilazapril; the resting plasma ANF value was not altered.	Cilazapril	93-103	natriuretic peptide A	Homo sapiens	11-14	
2534417-7	1989	These results suggest that the observed decrease in the plasma ANF level during exercise induced by cilazapril is, in part, related to an improvement in the cardiac overload, and that cilazapril may be effective in physically active hypertensive patients.	Cilazapril	100-110	natriuretic peptide A	Homo sapiens	63-66